BR9911043A - Composição para o tratamento do hiv e outras infecções viróticas - Google Patents
Composição para o tratamento do hiv e outras infecções viróticasInfo
- Publication number
- BR9911043A BR9911043A BR9911043-1A BR9911043A BR9911043A BR 9911043 A BR9911043 A BR 9911043A BR 9911043 A BR9911043 A BR 9911043A BR 9911043 A BR9911043 A BR 9911043A
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- treatment
- virus
- hydrogen
- carbon atoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Patente de Invenção: <B>"COMPOSIçãO PARA O TRATAMENTO DO HIV E OUTRAS INFECçõES VIRóTICAS"<D>. Uma composição farmacêutica que pode ser usada para o tratamento de infecções viróticas, de forma específica do HIV. A composição compreende a partir de cerca de 250 mg até cerca de 6000 mg de um derivado de benzimidazol da fórmula (I) ou um sal de adição, orgânico ou inorgânico, farmaceuticamente aceitável da mesma na qual X é hidrogênio, halogênio, alquila de menos do que 7 átomos de carbono ou alcóxi de menos do que 7 átomos de carbono; n é um número inteiro positivo de menos do que 4; Y é hidrogênio, cloro, nitro, oxicloro, metila ou etila; R é hidrogênio ou um grupo alquila a partir de 1 até 8 átomos de carbono; e R~ 2~ é 4-tiazolila. O composto de preferência é o tiabendazol. Na presente invenção foi descoberto que os compostos descritos acima são úteis para a inibição do HIV e para o tratamento da infecção por HIV quando usado de forma isolada ou em combinação com outro agente antivirótico. Essas composições podem impedir a replicação do vírus do HIV, impedir a criação de cepas de vírus que sejam resistentes ao tratamento com os benzimidazóis, impedir ou retardar a infecção de células com o vírus do HIV e retardar o reaparecimento do vírus em células tratadas. Essas composições também são eficazes contra a hepatite e vírus tais como os do herpes, influenza e rinovírus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8138498A | 1998-05-19 | 1998-05-19 | |
PCT/US1999/011059 WO1999059585A1 (en) | 1998-05-19 | 1999-05-19 | Compositions for the treatment of hiv and other viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9911043A true BR9911043A (pt) | 2001-02-13 |
Family
ID=22163807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9911043-1A BR9911043A (pt) | 1998-05-19 | 1999-05-19 | Composição para o tratamento do hiv e outras infecções viróticas |
Country Status (19)
Country | Link |
---|---|
US (1) | US6245789B1 (pt) |
EP (1) | EP1079831A1 (pt) |
JP (1) | JP2002515432A (pt) |
KR (1) | KR20010043709A (pt) |
CN (1) | CN1301158A (pt) |
AR (1) | AR019305A1 (pt) |
AU (1) | AU4004299A (pt) |
BR (1) | BR9911043A (pt) |
CA (1) | CA2329877A1 (pt) |
CO (1) | CO5050303A1 (pt) |
HU (1) | HUP0103319A2 (pt) |
ID (1) | ID27457A (pt) |
IL (1) | IL139002A0 (pt) |
NO (1) | NO20005839L (pt) |
PE (1) | PE20000550A1 (pt) |
PL (1) | PL344223A1 (pt) |
SK (1) | SK17442000A3 (pt) |
TR (1) | TR200003383T2 (pt) |
WO (1) | WO1999059585A1 (pt) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6479526B1 (en) | 1995-04-12 | 2002-11-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
US6262093B1 (en) | 1995-04-12 | 2001-07-17 | The Proctor & Gamble Company | Methods of treating cancer with benzimidazoles |
US6177460B1 (en) | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
US6265427B1 (en) | 1995-06-07 | 2001-07-24 | The Proctor & Gamble Company | Pharmaceutical composition for the method of treating leukemia |
US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
US6686391B2 (en) | 1995-08-04 | 2004-02-03 | University Of Arizona Foundation | N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions |
US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
US6506783B1 (en) * | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
US6423734B1 (en) | 1999-08-13 | 2002-07-23 | The Procter & Gamble Company | Method of preventing cancer |
US6242461B1 (en) * | 2000-01-25 | 2001-06-05 | Pfizer Inc. | Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
US6608096B1 (en) * | 2000-09-26 | 2003-08-19 | University Of Arizona Foundation | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6462062B1 (en) | 2000-09-26 | 2002-10-08 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6407105B1 (en) * | 2000-09-26 | 2002-06-18 | The Procter & Gamble Company | Compounds and methods for use thereof in the treatment of cancer or viral infections |
US6380232B1 (en) | 2000-09-26 | 2002-04-30 | The Procter & Gamble Company | Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof |
AU2002239395A1 (en) * | 2000-11-01 | 2002-06-03 | The Procter And Gamble Company | Hiv treatment with benzimidazoles |
DE60112609T2 (de) | 2000-12-15 | 2006-01-19 | Glaxo Group Ltd., Greenford | Pyrazolopyridine |
ES2243579T3 (es) | 2000-12-15 | 2005-12-01 | Glaxo Group Ltd | Derivados de pirazolopirideno. |
ATE274515T1 (de) | 2001-03-08 | 2004-09-15 | Smithkline Beecham Corp | Pyrazolopyridinderivate |
US7034030B2 (en) | 2001-03-30 | 2006-04-25 | Smithkline Beecham Corporation | Pyralopyridines, process for their preparation and use as therapeutic compounds |
WO2002083672A1 (en) | 2001-04-10 | 2002-10-24 | Smithkline Beecham Corporation | Antiviral pyrazolopyridine compounds |
DE60204452T2 (de) | 2001-04-27 | 2005-12-15 | Smithkline Beecham Corp. | Pyrazolo[1,5a]Pyridinderivate |
EP1401836B1 (en) * | 2001-06-21 | 2006-08-23 | SmithKline Beecham Corporation | Imidazo¬1,2-a|pyridine derivatives for the prophylaxis and treatment of herpes viral infections |
DE60211539T2 (de) | 2001-10-05 | 2006-09-21 | Smithkline Beecham Corp. | Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion |
DE60222465T2 (de) * | 2001-12-11 | 2008-06-05 | Smithkline Beecham Corp. | Pyrazolopyridin-derivate als antiherpesmittel |
US7022712B2 (en) * | 2002-03-26 | 2006-04-04 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Solubilization of weak bases |
WO2004033454A1 (en) | 2002-10-03 | 2004-04-22 | Smithkline Beecham Corporation | Therapeutic compounds based on pyrazolopyridine derivatives |
AU2003900064A0 (en) * | 2003-01-09 | 2003-01-23 | Penam Investments Pty. Ltd. | A method of treatment or prophylaxis of viral infection. |
JP2005060362A (ja) * | 2003-07-28 | 2005-03-10 | Shionogi & Co Ltd | セスキテルペン誘導体を含有する抗HIV剤、抗BVDV剤、抗HCV剤又は抗CoV剤 |
EP2251010A1 (en) | 2009-05-08 | 2010-11-17 | Sygnis Bioscience GmbH & Co. KG | Use of thiabendazole and derivatives thereof for the therapy of neurological conditions |
US9655962B2 (en) * | 2013-03-15 | 2017-05-23 | Camas Incorporated | Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities |
FR3057865A1 (fr) * | 2016-10-21 | 2018-04-27 | Laboratoire Michel Iderne | Composition chimique |
TW201936193A (zh) * | 2017-12-05 | 2019-09-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 使用組合產品治療rsv |
KR102342313B1 (ko) * | 2021-08-27 | 2021-12-24 | (주)바이오메트릭스 테크놀로지 | 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3010968A (en) | 1959-11-25 | 1961-11-28 | Du Pont | Process for manufacture of certain alkyl esters of benzimidazole carbamic acids |
NL134354C (pt) | 1963-05-23 | |||
US3499761A (en) | 1964-07-20 | 1970-03-10 | Gaf Corp | Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents |
US3541213A (en) | 1966-05-06 | 1970-11-17 | Du Pont | Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles |
US3881014A (en) | 1968-11-05 | 1975-04-29 | Bayer Ag | N-tritylimidazoles for treating fungal infections |
BE759337A (fr) | 1969-11-24 | 1971-05-24 | Lilly Co Eli | Benzimidazol (2,1-b)-quinazolin (6h) ones qui sont des immuno-depresseurs, et nouvelles benzimidazo (2,1-b) quinazolin-12-(6h) ones |
US3956262A (en) | 1970-12-09 | 1976-05-11 | Beecham Group Limited | Triazenoimidazoles |
US3738995A (en) | 1971-05-14 | 1973-06-12 | Du Pont | Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates |
FR2155888A1 (en) | 1971-10-13 | 1973-05-25 | Agot Aime | Solid anthelmintic composn - for more economical treatment of ruminants |
US4046906A (en) | 1973-04-21 | 1977-09-06 | Hoechst Aktiengesellschaft | Salts of alkyl 2-benzimidazole-carbamate |
HU193951B (en) | 1985-03-11 | 1987-12-28 | Richter Gedeon Vegyeszet | Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them |
US4731366A (en) | 1986-08-05 | 1988-03-15 | Harbor Branch Oceanographic Institution, Inc. | Discorhabdin compositions and their methods of use |
GB2210875B (en) | 1987-10-09 | 1991-05-29 | Farmos Oy | Aromatase inhibiting 4(5)-imidazoles |
US5329012A (en) | 1987-10-29 | 1994-07-12 | The Research Foundation Of State University Of New York | Bis(acyloxmethyl)imidazole compounds |
US5114951A (en) | 1989-04-11 | 1992-05-19 | Burroughs Wellcome Company | Agents for combating multiple drug resistance |
US5149527A (en) | 1990-09-18 | 1992-09-22 | Oncotech, Inc. | Immunopotentiating protocol for chemotherapy-responsive tumors |
US5364875A (en) | 1992-05-11 | 1994-11-15 | The Du Pont Merck Pharmaceutical Company | Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis |
US5310748A (en) | 1992-05-11 | 1994-05-10 | The Du Pont Merck Pharmaceutical Company | Imidazoles for the treatment of atherosclerosis |
US5290801A (en) | 1992-05-29 | 1994-03-01 | The Du Pont Merck Pharmaceutical Company | Benzimidazoles for the treatment of atherosclerosis |
AU4787693A (en) | 1992-08-12 | 1994-03-15 | Upjohn Company, The | Protein kinase inhibitors and related compounds combined with taxol |
SK279471B6 (sk) | 1993-03-31 | 1998-11-04 | Merck & Co. | Kompozícia zlúčenín, farmaceutické prostriedky s i |
US5434163A (en) | 1993-05-14 | 1995-07-18 | The Medical College Of Pennsylvania | Treatment of Cryptococcus neoformans infection |
JP3213471B2 (ja) | 1994-04-13 | 2001-10-02 | ポーラ化成工業株式会社 | 薬効成分含有リポソーム製剤の製造方法 |
US5656615A (en) | 1995-04-12 | 1997-08-12 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals |
NZ305784A (en) | 1995-04-12 | 2001-03-30 | Procter & Gamble | Benzimidazole containing medicaments for treating cancers, tumors and viral infections |
US5665713A (en) | 1995-04-12 | 1997-09-09 | Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
ZA962880B (en) | 1995-04-12 | 1997-03-17 | Procter & Gamble | A pharmaceutical composition for inhibiting the growth of viruses and cancers |
US5629341A (en) | 1995-04-12 | 1997-05-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of viruses and cancers |
ZA962879B (en) * | 1995-04-12 | 1997-03-17 | Procter & Gamble | A pharmaceutical composition for inhibiting the growth of viruses and cancers |
HUP9900901A3 (en) | 1995-04-12 | 1999-11-29 | Procter And Gamble Co Cincinna | A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers |
MX9707809A (es) | 1995-06-07 | 1998-01-31 | Procter & Gamble | Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres. |
US5665751A (en) | 1995-06-07 | 1997-09-09 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
WO1996040122A1 (en) | 1995-06-07 | 1996-12-19 | The Procter & Gamble Company | Use of benzimidazoles for the manufacture of a medicament for the treatment of leukemia |
US6200992B1 (en) | 1995-06-07 | 2001-03-13 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
US5770616A (en) | 1995-06-07 | 1998-06-23 | The Procter & Gamble Company | Pharmaceutical composition for inhibiting the growth of cancers |
TR199800244T2 (xx) | 1995-08-03 | 1998-09-21 | The Procter & Gamble Company | Griseofulvinin, kanserlerin ilerlemesini �nlemede kullan�m�. |
US5908855A (en) | 1996-07-16 | 1999-06-01 | The Procter & Gamble Company | Compositions for treating viral infections |
EP0841921A2 (en) | 1995-08-04 | 1998-05-20 | The Procter & Gamble Company | Use of fluconazole for inhibiting the growth of cancers |
US5900429A (en) | 1997-01-28 | 1999-05-04 | The Procter & Gamble Company | Method for inhibiting the growth of cancers |
US6506783B1 (en) | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
PE11499A1 (es) | 1997-05-16 | 1999-03-01 | Procter & Gamble | Tratamiento del hiv y cancer |
US6245789B1 (en) | 1998-05-19 | 2001-06-12 | The Procter & Gamble Company | HIV and viral treatment |
-
1999
- 1999-05-17 US US09/312,949 patent/US6245789B1/en not_active Expired - Fee Related
- 1999-05-19 CA CA002329877A patent/CA2329877A1/en not_active Abandoned
- 1999-05-19 PL PL99344223A patent/PL344223A1/xx unknown
- 1999-05-19 CO CO99030834A patent/CO5050303A1/es unknown
- 1999-05-19 EP EP99923219A patent/EP1079831A1/en not_active Withdrawn
- 1999-05-19 AU AU40042/99A patent/AU4004299A/en not_active Abandoned
- 1999-05-19 WO PCT/US1999/011059 patent/WO1999059585A1/en not_active Application Discontinuation
- 1999-05-19 IL IL13900299A patent/IL139002A0/xx unknown
- 1999-05-19 PE PE1999000422A patent/PE20000550A1/es not_active Application Discontinuation
- 1999-05-19 CN CN99806363A patent/CN1301158A/zh active Pending
- 1999-05-19 AR ARP990102384A patent/AR019305A1/es unknown
- 1999-05-19 HU HU0103319A patent/HUP0103319A2/hu unknown
- 1999-05-19 JP JP2000549250A patent/JP2002515432A/ja not_active Withdrawn
- 1999-05-19 ID IDW20002656A patent/ID27457A/id unknown
- 1999-05-19 TR TR2000/03383T patent/TR200003383T2/xx unknown
- 1999-05-19 BR BR9911043-1A patent/BR9911043A/pt not_active IP Right Cessation
- 1999-05-19 KR KR1020007012938A patent/KR20010043709A/ko not_active Application Discontinuation
- 1999-05-19 SK SK1744-2000A patent/SK17442000A3/sk unknown
-
2000
- 2000-11-17 NO NO20005839A patent/NO20005839L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1079831A1 (en) | 2001-03-07 |
HUP0103319A2 (hu) | 2002-05-29 |
CA2329877A1 (en) | 1999-11-25 |
JP2002515432A (ja) | 2002-05-28 |
CN1301158A (zh) | 2001-06-27 |
KR20010043709A (ko) | 2001-05-25 |
NO20005839L (no) | 2001-01-16 |
AU4004299A (en) | 1999-12-06 |
ID27457A (id) | 2001-04-12 |
US6245789B1 (en) | 2001-06-12 |
TR200003383T2 (tr) | 2001-03-21 |
PL344223A1 (en) | 2001-10-08 |
CO5050303A1 (es) | 2001-06-27 |
AR019305A1 (es) | 2002-02-13 |
IL139002A0 (en) | 2001-11-25 |
SK17442000A3 (sk) | 2001-08-06 |
WO1999059585A1 (en) | 1999-11-25 |
PE20000550A1 (es) | 2000-06-29 |
NO20005839D0 (no) | 2000-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9911043A (pt) | Composição para o tratamento do hiv e outras infecções viróticas | |
CO5160294A1 (es) | Composicion farmaceutica que inhibe o detiene el crecimiento de virus en animales particularmente mamiferos sarrollo de virus en animales y composiciones farmaceuticas que los contienen | |
TW427887B (en) | Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections | |
BR0312271A (pt) | compostos, composições e seus usos para o tratamento de infecções por flaviviridae | |
BR0313743A (pt) | Benzimidazol quinolinonas e usos destas | |
BR0111127A (pt) | Métodos e composições para tratamento do vìrus de hepatite c | |
UY27466A1 (es) | Métodos y composiciones para el tratamiento de hepatitis c virus con 4'-modificaciones nucleosides | |
CL2008003431A1 (es) | Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih. | |
RS114104A (en) | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections | |
CO5200778A1 (es) | Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis | |
BRPI0510414A (pt) | uso de derivados de quinolina substituìdos para o tratamento de doenças micobacterianas resistentes a fármacos | |
BRPI9912896B8 (pt) | ß-l-2' -desoxinucleosídeos para tratamento de hepatite b | |
HUP0001170A2 (hu) | Hatóanyagként enzimidazol-2-karbamát-származékokat tartalmazó, vírusfertőzések és rák kezelésére alkalmas gyógyszerkészítmények | |
EA200500846A1 (ru) | Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации | |
SG171596A1 (en) | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis c virus | |
BRPI0508079A (pt) | composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c | |
ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
EA200600227A1 (ru) | Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов | |
BR0107912A (pt) | Composto, composições, e, métodos para tratar ou prevenir o c ncer ou doença neoplástica, método para inibir o desenvolvimento de uma célula cancerìgena ou célula neoplástica, método para tratar ou prevenir uma infecção viral em um paciente, e para inibir a replicação ou a infectividade de um vìrus | |
CO5160292A1 (es) | Composicion farmaceutica que contiene derivados de 2-tienil- imidazolo[4,5]piridina, util para el tratamiento de infeccio nes virales | |
WO2007106450A3 (en) | Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase in combination therapy | |
BR0314695A (pt) | Composto, processo para preparar um composto, processo para preparar um estereoisÈmero de um composto, composição para o tratamento de doenças virais, e, composição para o tratamento da hepatite b | |
AR003137A1 (es) | Una composicion farmaceutica para tratar la leucemia | |
KR910000734A (ko) | 네플라노신 유도체 | |
JP2023518390A (ja) | ウイルス感染症の治療若しくは予防又はウイルス感染症の発生を制限するための方法及び組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A, 5A, 6A, 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007. |